FRAMINGHAM, MA — March 13, 2026 — Leads & Copy —
Xenetic Biosciences, Inc. (NASDAQ:XBIO) reported its financial results for the year ended December 31, 2025, highlighting progress in its DNase-based technology for treating difficult-to-treat cancers. The company ended the year with $7.9 million in cash to fund operations.
The biopharmaceutical company is focused on advancing innovative immuno-oncology technologies. Recent highlights include expanded preclinical and translational evidence supporting neutrophil extracellular traps (NETs) as drivers of cancer progression and the therapeutic potential of Deoxyribonuclease (DNase)-based interventions.
Xenetic is progressing investigator-initiated exploratory studies in Israel evaluating DNase I in combination with standard-of-care and immunotherapy platforms. These include an ongoing pancreatic ductal adenocarcinoma (PDAC) study and a proposed large B-cell lymphoma (LBCL) study in combination with Chimeric Antigen Receptor (CAR) T cell therapy.
The company is also advancing clinical manufacturing activities for DNase I toward an Investigational New Drug (IND) application, with a current focus on mechanism-of-action and translational research studies supported by encouraging CAR-T proof-of-concept studies with Scripps Research.
James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, stated that the company strengthened the evidence linking NETs to cancer progression and the therapeutic promise of DNase-based strategies, advanced multiple investigator-initiated studies, and progressed toward IND-enabling activities. Parslow added that these efforts position the Company well as it moves through 2026, while remaining disciplined in its use of capital and focused on creating long-term shareholder value.
Xenetic continues to advance its DNase-based technology toward Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. In 2025, the company completed preclinical studies evaluating DNase I in combination with chemotherapy, immunotherapies, and CAR-T approaches across both solid and hematologic cancer models. Data generated from these studies are informing ongoing translational work and manufacturing activities as the Company progresses toward U.S. IND submission.
The company is pursuing strategic alternatives to maximize shareholder value.
The net loss for the year ended December 31, 2025, was approximately $2.7 million. Royalty revenue from the company’s sublicense with Takeda Pharmaceuticals Co. Ltd increased approximately 19% to $3.0 million in the year ended December 31, 2025, from $2.5 million for the year ended December 31, 2024. Research and development expenses for the year ended December 31, 2025 decreased by approximately $0.2 million, or 7%, to $3.1 million from $3.3 million in the prior year period. General and administrative expenses for the year ended December 31, 2025 were $2.7 million, decreasing by approximately $0.7 million, or 20%, compared to the prior year.
The company ended the year with approximately $7.9 million of cash, representing an increase of approximately $1.7 million compared to the prior year-end, primarily due to net proceeds of approximately $4.0 million from an underwritten public offering completed in October 2025.
Xenetic Biosciences, Inc. is focused on advancing innovative immuno-oncology technologies addressing difficult-to-treat cancers. The company’s proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Source: Xenetic Biosciences, Inc.
